The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition is a public research consortium which was founded on November 28, 2006 financed by the Instituto de Salud Carlos III and the Ministerio de Ciencia e Innovación .The CIBERObn gathers 25 investigation groups from different Spanish Hospitals, Universities and Research Centres. Its mission is to promote a better knowledge about the mechanisms contributing to obesity development in order to reduce its incidence and prevalence, as well as its complications, in addition to nutrition-related diseases.The CIBERObn is structured into 8 scientific programs intended to increase the collaboration between researchers, to strengthen synergies and to boost new research lines. Programs are as follows: Nutrition: effects of different types of diet and nutrients on human health. Adipobiology: identification of new signals released by the adipose tissue which are involved in the regulation of energy homeostasis. Obesity and Cancer: role of those proteins associated with cell cycle on metabolic control and obesity development. Obesity and Cardiovascular risk: hemodynamic, metabolic and inflammatory factors associated to cardiac and vascular diseases in obesity. Neurocognitive and Environmental Factors: environmental and emotional factors in nutrition and obesity disorders. Obesity in Childhood-Adolescence Period: biochemical, hormonal, metabolic, genetic, proteomic and body-composition study in children and adolescents. Biomarkers: new strategies, therapeutic and prevention technologies, biomarkers of obesity. Biological Models and Therapeutic Targets: development and validation of experimental models and therapeutic targets in case of obesity.Additionally, CIBERObn lays a particular emphasis on translational research, specially focusing on research transfer to clinical applications and practices. To this end, two cross-cutting programs have been created: Staff Training and Recruitment, which is intended to train our staff according to our research lines and priorities “Fat Bank” Structural Program: biobank infrastructure connecting the above mentioned programs in a cross way by contributing with common solutions.The Fat Bank is a strategic platform of the CIBERobn which offers the Scientific Community different kinds of biological material which are associated to thorough metabolic phenotyping. This information is entered by means of a tailor-made individualised software. This fat-bank- launched in 2009- currently contains 3000 samples of biologic material from more than 300 individuals. In 2009, 287 indexed articles were published. Their average impact factor is 4.05, which is very high for this subject area. Of them, 67 belong to the first decile and 105 more belong to the first quartile of the subject area of indexed journals. They accumulate a total impact factor of 1,165. Provisional data of 2010 show an increase of 10%, highly improving the international visibility of the consortium. Wikipedia.
Lott I.T.,University of California at Irvine |
Dierssen M.,CIBER ISCIII
The Lancet Neurology | Year: 2010
Improvements in medical interventions for people with Down's syndrome have led to a substantial increase in their longevity. Diagnosis and treatment of neurological complications are important in maintaining optimal cognitive functioning. The cognitive phenotype in Down's syndrome is characterised by impairments in morphosyntax, verbal short-term memory, and explicit long-term memory. However, visuospatial short-term memory, associative learning, and implicit long-term memory functions are preserved. Seizures are associated with cognitive decline and seem to cause additional decline in cognitive functioning, particularly in people with Down's syndrome and comorbid disorders such as autism. Vision and hearing disorders as well as hypothyroidism can negatively impact cognitive functioning in people with Down's syndrome. Dementia that resembles Alzheimer's disease is common in adults with Down's syndrome. Early-onset dementia in adults with Down's syndrome does not seem to be associated with atherosclerotic complications. © 2010 Elsevier Ltd. All rights reserved. Source
Quirce S.,CIBER ISCIII
Current Opinion in Allergy and Clinical Immunology | Year: 2014
PURPOSE OF REVIEW: To evaluate recent data on the causative role of specific IgE antibodies, as well as the performance of IgE diagnostic tests, in allergic occupational asthma induced by high (HMW) or low-molecular-weight (LMW) agents. RECENT FINDINGS: Skin prick testing (SPT) and specific IgE assays are useful to document allergy to most HMW allergens and some LMW agents. These tests, however, are limited by the lack of standardized and commercially available reagents. There is a wide variability among the quality of occupational allergen extracts used for SPT and the sensitivity of several SPT solutions is low. In addition, many individuals with allergen-specific serum IgE and/or positive SPT to specific HMW allergens do not have clinical symptoms. Sensitization or allergenic cross-reactivity to allergens or epitopes from unrelated sources may interfere in the diagnosis of IgE-mediated allergy, giving rise to false-positive results, particularly when cross-reactive carbohydrate determinants (CCDs) are involved. The immune responses to these ubiquitous structures may interfere with the diagnosis of occupational allergy. Component-resolved diagnosis of IgE-mediated allergic diseases (occupational and nonoccupational) using panels of native or recombinant allergens, or micro-arrayed allergens, have been proposed to identify specific molecules responsible for these disorders and to overcome false-positive in-vitro test results. SUMMARY: Improvement and standardization of SPT solutions for occupational allergens are highly recommended. More refined diagnostic tools than specific IgE measurements are being developed, such as inhibition assays of IgE binding to CCDs with specific carbohydrate molecules, and component-resolved diagnosis. © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source
Carod-Artal F.J.,Virgen de la Luz Hospital |
Gascon J.,CIBER ISCIII
The Lancet Neurology | Year: 2010
Chagas disease is a neglected infectious disease in the tropics and an emerging health problem in Europe and the USA. In the past decade, a link has been recorded between ischaemic stroke and Trypanosoma cruzi infection in several epidemiological studies, and an increase in stroke prevalence is expected with the ageing of the population infected with T cruzi in Latin America. Heart failure, mural thrombus, left ventricular apical aneurysm, and several types of cardiac arrhythmias are associated with stroke in Chagas disease. Stroke could also be the first sign of Chagas disease in asymptomatic patients and those with mild systolic dysfunction, so patients with stroke who are from endemic regions should be screened for T cruzi infection. The most frequent stroke syndrome seen in patients with Chagas disease is partial anterior circulation infarction. Stroke recurrence has been estimated to occur in 20% of patients, and secondary prevention measures include chronic anticoagulation in cardioembolic chagasic stroke. So far, no studies have been done to assess the effect of chagasic stroke on vascular dementia. © 2010 Elsevier Ltd. All rights reserved. Source
Technical University of Madrid, Fundacion Para La Investigacion Biomedica Del Hospital, Ciber Isciii and University Autonomoa Of Madrid | Date: 2012-06-27
The present invention describes an ocular device comprising a magnetic eye implant and a ferrofluid. The products of the invention solve the problems of the patients position and contribute to the increase in the success rate of the surgical procedure for correcting retinal detachment, problems of severe proliferative diabetic retinopathy in those incapable of maintaining posture, of infectious retinitis, problems resulting from traumatisms and endophthalmitis. It is also possible to use the device as an auxiliary surgical element, e.g., for extracting subretinal fluid.
Ciber Isciii | Date: 2013-06-13
An inactivated mycobacteria for oral use in the prevention of tuberculosis, which are administered using a multi-dose regimen and with a reduced time interval between doses, such as to induce a tolerance-building to infection by the tubercle